Literature DB >> 22842765

Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice.

José L Moreno1, Terrell Holloway, Adrienne Umali, Vinayak Rayannavar, Stuart C Sealfon, Javier González-Maeso.   

Abstract

RATIONALE: In schizophrenia patients, optimal treatment with antipsychotics requires weeks to months of sustained drug therapy. However, single administration of antipsychotic drugs can reverse schizophrenia-like behavioral alterations in rodent models of psychosis. This raises questions about the physiological relevance of such antipsychotic-like activity.
OBJECTIVE: This study evaluates the effects of chronic treatment with clozapine on the cellular and behavioral responses induced by the hallucinogenic serotonin 5-HT(2A) receptor agonist lysergic acid diethylamide (LSD) as a mouse model of psychosis.
METHOD: Mice were treated chronically (21 days) with 25 mg/kg/day clozapine. Experiments were conducted 1, 7, 14, and 21 days after the last clozapine administration. [(3)H]Ketanserin binding and 5-HT ( 2A ) mRNA expression were determined in mouse somatosensory cortex. Head-twitch behavior, expression of c-fos, which is induced by all 5-HT(2A) agonists, and expression of egr-1 and egr-2, which are LSD-like specific, were assayed.
RESULTS: Head-twitch response was decreased and [(3)H]ketanserin binding was downregulated in 1, 7, and 14 days after chronic clozapine. 5-HT ( 2A ) mRNA was reduced 1 day after chronic clozapine. Induction of c-fos, but not egr-1 and egr-2, was rescued 7 days after chronic clozapine. These effects were not observed after short treatment (2 days) with clozapine or chronic haloperidol (1 mg/kg/day).
CONCLUSION: Our findings provide a murine model of chronic atypical antipsychotic drug action and suggest downregulation of the 5-HT(2A) receptor as a potential mechanism involved in these persistent therapeutic-like effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22842765      PMCID: PMC3552490          DOI: 10.1007/s00213-012-2809-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  59 in total

1.  Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected.

Authors:  Ofer Agid; Shitij Kapur; Tamara Arenovich; Robert B Zipursky
Journal:  Arch Gen Psychiatry       Date:  2003-12

Review 2.  Schizophrenia.

Authors:  Robert Freedman
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

3.  DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release.

Authors:  J Ichikawa; J Dai; H Y Meltzer
Journal:  Brain Res       Date:  2001-07-13       Impact factor: 3.252

4.  Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/-)DOI] in C57BL/6J mice.

Authors:  Randy L Smith; Robert J Barrett; Elaine Sanders-Bush
Journal:  Psychopharmacology (Berl)       Date:  2002-12-10       Impact factor: 4.530

5.  Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains.

Authors:  A Ouagazzal; A J Grottick; J Moreau; G A Higgins
Journal:  Neuropsychopharmacology       Date:  2001-10       Impact factor: 7.853

6.  Antipsychotic drug treatment induces differential gene expression in the rat cortex.

Authors:  Outi Kontkanen; Petri Törönen; Merja Lakso; Garry Wong; Eero Castrén
Journal:  J Neurochem       Date:  2002-12       Impact factor: 5.372

Review 7.  Schizophrenia: diverse approaches to a complex disease.

Authors:  Akira Sawa; Solomon H Snyder
Journal:  Science       Date:  2002-04-26       Impact factor: 47.728

8.  Chronic antipsychotic drug treatment induces long-lasting expression of fos and jun family genes and activator protein 1 complex in the rat prefrontal cortex.

Authors:  Outi Kontkanen; Merja Lakso; Garry Wong; Eero Castrén
Journal:  Neuropsychopharmacology       Date:  2002-08       Impact factor: 7.853

Review 9.  Hallucinogens.

Authors:  David E Nichols
Journal:  Pharmacol Ther       Date:  2004-02       Impact factor: 12.310

10.  Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex.

Authors:  Javier González-Maeso; Tony Yuen; Barbara J Ebersole; Elisa Wurmbach; Alena Lira; Mingming Zhou; Noelia Weisstaub; Rene Hen; Jay A Gingrich; Stuart C Sealfon
Journal:  J Neurosci       Date:  2003-10-01       Impact factor: 6.167

View more
  13 in total

1.  HDAC2-dependent Antipsychotic-like Effects of Chronic Treatment with the HDAC Inhibitor SAHA in Mice.

Authors:  Mario de la Fuente Revenga; Daisuke Ibi; Justin M Saunders; Travis Cuddy; Maryum K Ijaz; Rudy Toneatti; Mitsumasa Kurita; Terrell Holloway; Li Shen; Jeremy Seto; Mikhail G Dozmorov; Javier González-Maeso
Journal:  Neuroscience       Date:  2018-07-17       Impact factor: 3.590

2.  Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects.

Authors:  Daisuke Ibi; Mario de la Fuente Revenga; Nebojsa Kezunovic; Carolina Muguruza; Justin M Saunders; Supriya A Gaitonde; José L Moreno; Maryum K Ijaz; Vishaka Santosh; Alexey Kozlenkov; Terrell Holloway; Jeremy Seto; Aintzane García-Bea; Mitsumasa Kurita; Grace E Mosley; Yan Jiang; Daniel J Christoffel; Luis F Callado; Scott J Russo; Stella Dracheva; Juan F López-Giménez; Yongchao Ge; Carlos R Escalante; J Javier Meana; Schahram Akbarian; George W Huntley; Javier González-Maeso
Journal:  Nat Neurosci       Date:  2017-08-07       Impact factor: 24.884

Review 3.  Preclinical models of antipsychotic drug action.

Authors:  José L Moreno; Javier González-Maeso
Journal:  Int J Neuropsychopharmacol       Date:  2013-06-10       Impact factor: 5.176

Review 4.  Epigenetic Mechanisms of Serotonin Signaling.

Authors:  Terrell Holloway; Javier González-Maeso
Journal:  ACS Chem Neurosci       Date:  2015-03-10       Impact factor: 4.418

5.  Sex-specific role for serotonin 5-HT2A receptor in modulation of opioid-induced antinociception and reward in mice.

Authors:  Salvador Sierra; Karan H Muchhala; Donald K Jessup; Katherine M Contreras; Urjita H Shah; David L Stevens; Jennifer Jimenez; Xiomara K Cuno Lavilla; Mario de la Fuente Revenga; Kumiko M Lippold; Shanwei Shen; Justin L Poklis; Liya Y Qiao; William L Dewey; Hamid I Akbarali; M Imad Damaj; Javier González-Maeso
Journal:  Neuropharmacology       Date:  2022-02-17       Impact factor: 5.273

6.  Repressive epigenetic changes at the mGlu2 promoter in frontal cortex of 5-HT2A knockout mice.

Authors:  Mitsumasa Kurita; José L Moreno; Terrell Holloway; Alexey Kozlenkov; Giuseppe Mocci; Aintzane García-Bea; James B Hanks; Rachael Neve; Eric J Nestler; Scott J Russo; Javier González-Maeso
Journal:  Mol Pharmacol       Date:  2013-03-18       Impact factor: 4.436

7.  Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a βarrestin2-independent activation of Akt.

Authors:  Cullen L Schmid; John M Streicher; Herbert Y Meltzer; Laura M Bohn
Journal:  Neuropsychopharmacology       Date:  2014-02-17       Impact factor: 7.853

8.  Role of mGlu2 in the 5-HT2A receptor-dependent antipsychotic activity of clozapine in mice.

Authors:  Kelsey S Hideshima; Ashkhan Hojati; Justin M Saunders; Doan M On; Mario de la Fuente Revenga; Jong M Shin; Ana Sánchez-González; Cassandra M Dunn; Alexander B Pais; Anthony C Pais; Michael F Miles; Jennifer T Wolstenholme; Javier González-Maeso
Journal:  Psychopharmacology (Berl)       Date:  2018-09-12       Impact factor: 4.530

Review 9.  d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.

Authors:  Danilo De Gregorio; Stefano Comai; Luca Posa; Gabriella Gobbi
Journal:  Int J Mol Sci       Date:  2016-11-23       Impact factor: 5.923

10.  The effect of clozapine on mRNA expression for genes encoding G protein-coupled receptors and the protein components of clathrin-mediated endocytosis.

Authors:  Sally I Sharp; Ying Hu; Jon F Weymer; Mie Rizig; Andrew McQuillin; Stephen P Hunt; Hugh M D Gurling
Journal:  Psychiatr Genet       Date:  2013-08       Impact factor: 2.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.